|
|
|
|
|
|
by bhaavan
1966 days ago
|
|
|
91.6% is a good efficacy. Do they have plans to test it against other variants (E501Y mutation)?
Ideally this + the adenovirus based AZD122 seems to be the best combination of (efficacy, affordablility, and logistically feasibility) end for the pandemic.
https://www.gavi.org/vaccineswork/coronavirus-why-combining-... is another such article which talks about it. |
|
|